An Exploratory Study to Evaluate a Digital Intervention to Disrupt Scratching in Atopic Dermatitis and Psoriasis

Recruiting in Palo Alto (17 mi)

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: Click Therapeutics, Inc.

No Placebo Group

Trial Summary

What is the purpose of this trial?This trial tests a software to help patients with skin conditions like atopic dermatitis and psoriasis by improving brain functions related to various aspects of health.

Eligibility Criteria

This trial is for individuals with skin conditions like atopic dermatitis, eczema, or psoriasis. Participants should be interested in trying a digital intervention aimed at reducing scratching behavior.

Inclusion Criteria

Has an active email address and is willing and able to receive and respond to email messages

Lives in the United States

Is the sole user of an iPhone with an iPhone operating system (OS) 14 or later or a smartphone with an Android OS 10 or later for the duration of the study

+7 more

Exclusion Criteria

Pregnant or planning to become pregnant

I haven't started or changed my main cancer treatment in the last 30 days.

I currently have a skin infection.

+7 more

Participant Groups

The study tests two versions of CT-100, a software platform with interactive components designed to disrupt scratching by targeting neural systems related to various sensory and cognitive processes.

4Treatment groups

Experimental Treatment

Placebo Group

Group I: CT-100-004-A PsoriasisExperimental Treatment1 Intervention

Group II: CT-100-004-A Atopic DermatitisExperimental Treatment1 Intervention

Group III: CT-100-004-B PsoriasisPlacebo Group1 Intervention

Group IV: CT-100-004-B Atopic DermatitisPlacebo Group1 Intervention